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ABSTRACT:
The objective of this project is to report oncologic and functional outcomes
for a cohort of patients with supraglottic squamous cell carcinoma (SSCC) treated
in a multidisciplinary setting including the use of transoral laser microsurgery
(TLM). A retrospective observational study at Yale New Haven Hospital,
academic teaching hospital was performed. A total of 56 patients without
evidence of distant metastasis at presentation treated for SSCC between
January 1, 2003 and December 31, 2007 were identified. The main outcome
measures include overall survival (OS), locoregional and distant recurrence, and
the incidence of tracheostomy and gastrostomy tube requirement.
Of the 56 patients, 22 (39%) were treated with TLM, 23 (41%) with
definitive radiation (XRT) based therapy, and 11 (20%) with total laryngectomy
(TL). Chronic tracheostomy requirement for the TLM, XRT, and TL groups was
0% (0/21), 35% (7/20) and 100% (11/11). Long term gastrostomy tube (PEG)
use for the TLM, XRT, and TL groups was 15% (3/20), 36% (4/11) and 50%
(5/10) respectively. Two year OS for TLM, TL, and XRT were 86% (18/21), 80%
(8/10), and 52% (12/23) respectively. Controlling for age, stage, and treatment
on multivariate analysis, younger age and treatment with either TL or TLM were
significantly associated with improved survival.
In conclusion, transoral laser microsurgery, especially when employed in a
multimodal approach including adjuvant chemoradiotherapy, offers acceptable
oncologic results and good functional outcomes.
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INTRODUCTION

Supraglottic squamous cell carcinoma is a challenging disease affecting the parts
of the human body involved in how a person interacts in the world. There has
been considerable advancement in the available treatment options for
supraglottic SCCA over the past decades. Currently, the goal of treatment is to
optimize the chance of cure while minimizing the impact of therapy on a person’s
quality of life. This paper will discuss and investigate the current state of
treatment for supraglottic cancer.

EPIDEMIOLOGY:

Cancer of the head and neck most commonly affects regions of the aerodigestive
tract. Head and neck cancer comprises primary malignancies located in
anatomically related regions including the oral cavity, oropharynx, nasopharynx,
larynx, and hypopharynx. When taken in conglomerate, head and neck cancer
has the sixth greatest incidence worldwide, with approximately 600,000 new
cases annually. 1 More than 40,000 new cases of head and neck cancer in the
United States are diagnosed annually. Men are two to three times more likely to
be diagnosed with HNSCC than women and the median age of diagnosis is 60
years old. However, recent observations suggest that the number of new cases
in young adults may be increasing. 2 Tumor types consist predominantly of
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squamous cell carcinoma involving the upper aerodigestive tract and account for
greater than 90%, of head and neck cancers. 1 Because of the overwhelming
majority of squamous cell cancer, it will be the focus of discussion.

RISK FACTORS:

The major risk factors for head and neck squamous cell carcinoma include
exposure to tobacco, particularly through smoking, and alcohol. Together
smoking and alcohol consumption demonstrate a synergistic effect on the risk of
developing HNSCC since both smoking and alcohol consumption directly
traumatize mucosal surfaces. 1 Furthermore, exposure to tobacco smoke and
alcohol increases the burden of carcinogenic compounds presented to the
epithelial tissues. Smoking confers a dose related risk with duration of use more
important that intensity. 2 Alcohol is less important as an independent
carcinogenic agent except with profound use. However, alcohol exposure
exacerbates the complex carcinogenic effects of tobacco. Enzymatic systems
important in detoxifying carcinogens exhibit polymorphisms that add to the
genetic propensity for mutagenesis. 2

In addition to toxic exposure from tobacco and alcohol, infection with certain
viruses has been described to cause HNSCC. Of particular interest, human
papilloma virus (HPV) increases the risk of developing HNSCC. 1 Most
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implicated are HPV variants 16 and 18. 2 These variants encode oncogenes E6
and E7. The tumor-suppressor gene p53 is downregulated by E6 while E7
suppresses pRB. 2 HPV-related tumors are primarily located in the oropharynx
and behave as a unique malignancy when compared to tumors caused by
exposure to tobacco and alcohol. 1 As this discussion will focus on supraglottic
carcinoma, it is beyond the scope of this paper to address HPV in its entirety.

EMBRYOLOGY:

The larynx is an elegant structure designed to allow phonation and help establish
safe deglutition. Embryologic development subdivides the larynx into the
supraglottis, glottis, and subglottis. The embryologic origin of the laryngeal
subsites are important with regards to vascular and lymphatic anatomy as well as
epithelial cellular structure. These differences affect the clinical behavior of
tumors presenting in each subsite.

The supraglottis originates from the buccopharyngeal primordium of the third and
fourth branchial arches. 1 The supraglottis contains the suprahyoid and
infrahyoid epiglottis, aryepiglottic folds, arytenoids, and ventricular bands; also
known as the false cords. The embryologic development leads to arterial supply
from the superior laryngeal arteries with accompanying bilateral lymphatic
drainage. 1 Drainage, then, follows the superior laryngeal arteries to the carotid
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sheath and further to the deep cervical chain in neck levels II and III. 3 The
epithelium is composed of pseudostratified columnar cells in all areas except the
lateral aryepiglottic folds and lateral epiglottis which are stratified squamous cells.
Lymphatic vessels are quite superficial in the supraglottis, and with bilateral
drainage, the risk of bilateral nodal metastasis at presentation is more likely. For
this reason, supraglottic malignancies tend to present at a more advance stage.1

The glottis and subglottis are formed from the tracheobronchial premordium of
the sixth branchial arch and involves and fusion of the lateral furrows. 1 The
glottis contains the true vocal cords and associated anterior and posterior
commissures. The arterial supply designated by this embryologic development is
the inferior laryngeal arteries with associated lymphatic drainage. The lateral
union of the furrows creates a unilateral arterial supply and drainage of the glottis
and subglottis. Drainage of lymph follows the inferior laryngeal arteries to the
prelaryngeal and pretracheal lymph nodes in neck level VI and further to the
deep cervical chain in level IV. 3 The epithelium in this territory is made up of
stratified squamous cells with three layers of lamina propria. This leads to a
deeper level of lymph drainage meaning that a tumor must invade more deeply
before entering the lymphatic system. 1 This decreases the incidence of nodal
metastasis at presentation and, due to the unilateral drainage pattern, tends to be
unilateral unless the T stage is more advanced. 4
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ANATOMY:

The laryngeal superstructure includes one paired arytenoid cartilage and three
unpaired cartilages: the epiglottis, thyroid cartilage, and cricoid cartilage. The
superior borders of the larynx include the superior surface of the epiglottis as well
as the superior edge of the aryepiglottic folds. The lingual surface of the
suprahyoid epiglottis and the hyoepiglottic ligament make up the anterosuperior
border. Anterior borders of the larynx are the thyrohyoid membrane in the
supraglottis, the thyroid cartilage in the glottis, and the cricothyroid membrane
and the anterior arch of the cricoid cartilage in the subglottis. The inferior edge is
designated by a horizontal plane through the inferior edge of the cricoid cartilage.
The aryepiglottic folds, arytenoid cartilages, interarytenoid space, and the
posterior surface of the subglottic region comprise the posterior and lateral
borders of the larynx. Image 1 demonstrates the basic laryngeal structure. 1

From an oncologic perspective, the most important anatomic details of the larynx
are barriers to tumor spread and pathways that permit further tumor growth.
Barriers to tumor progression within the larynx include the cartilaginous and
ligamentous structures. The conus elasticus, a thick fibroelastic structure in the
glottic/subglottic region also prevents spread as does the cricothyroid
membrane.1 The anterior commissure of the vocal cords also seems to be a
barrier to glottic tumor spread. Two main spaces are recognized as pathways
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allowing spread of tumors within the larynx- the pre-epiglottic space and the
paraglottic space (Image 2). 1

Due to fenestrations in the epiglottic cartilage, the pre-epiglottic space (Image 2),
which contains only fat and areolar tissue, can be invaded by tumor. 5 The preepiglottic space is bounded superiorly by the hyoid bone, the hyoepiglottic
ligament, and the valleculae of the hypopharynx. The thyroid cartilage and the
thyrohyoid membrane form the anterior border with the epiglottic cartilage and
thyroepiglottic ligment make up the posterior border. Laterally and inferiorly the
pre-epiglottic space communicates with the paraglottic space. 6 Lymphatic
vessels drain the paraglottic space bilaterally to neck zone II and III. 3

The paraglottic space (Image 2) is prognostically important because progression
of tumor into this potential space allows for spread to all three regions of the
larynx, creating a transglottic neoplasm. 1 The space lies lateral to the true and
false cords. Superiorly it is in continuity with the pre-epiglottic space. The medial
borders are the quadragular membrane, an elastic supporting structure of the
supraglottis, the conus elasticus, and the laryngeal ventricles. Laterally, the
thyroid cartilage and the pyriform sinus of the hypopharynx create borders. The
space progresses inferiorly to the cricothyroid membrane. Glottic and
supraglottic lesions are stages T3 if they involve the paraglottic space. 4

Image 1: Anatomy of the laryngeal sites. !
Image from Cummings - Head and Neck surgery [1]

Image 2: Anatomy of the pre-epiglottic and paraglottic spaces !
Image from Cummings - Head and Neck surgery [1]
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STAGING:

Staging follows the tenants of the TNM staging system to describe the extent and
severity of a tumor. Tumor characteristics including size and invasion generate
the T stage. Presence and laterality of nodal involvement provide N staging.
The M stage refers to presence of metastatic disease. By design, the overall
stage of disease provides prognostic relevance. Each characteristic is important
in isolation, however, nodal spread and metastasis are particularly prognostic.
TNM staging can carry two important prefixes - clinical or pathologic TNM
staging. Clinical examination and radiographic reveals a clinical (cTNM) stage.
Biopsy of post-operative histopathology reveals a tumor’s pathologic (pTNM)
stage. A discussion of supraglottic staging with regards to prognosis will be
discussed in a different section.

In addition to TNM staging, the American Joint Commission on Cancer (AJCC)
created a classification that weighs T, N, and M status to produce a stage I-IVc. 4
AJCC staging offers a more simplified classification scheme that includes the
prognostic relevance of nodal disease and metastasis. The staging system
demonstrates the prognostic significance of metastasis - any M1 tumor is
automatically classified as stage IV. 4 The AJCC staging also demonstrates the
importance of nodal involvement as a tumor with any nodal involvement is at
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least stage III while more advanced nodal disease such as bilaterality upstages
the tumor to stage IVa. 4

T STAGE:

The T stage in laryngeal cancer depends on the subsite involved. Since the
focus of this paper is on supraglottic cancer, only supraglottic T staging will be
described. The T stage is categorized based on sites of invasion, vocal cord
fixation, cartilaginous invasion, and extra-laryngeal involvement. T1 lesions are
localized to a single subsite of the supraglottis with retained vocal cord function.
Invasion of more than one supraglottic subsite, glottic involvement, or spread to
local mucosal surfaces of the valleculae, base of tongue, or pyriform sinus
advance the stage to T2. 4 Normal vocal cord function without fixation must be
present in T2 lesions. Vocal cord fixation automatically upstages a tumor to T3. 4
Invasion of the pre-epiglottic space, paraglottic space, post cricoid region, or
minimal invasion into the inner cortex of the thyroid cartilage begets a T3 lesion
as well. 4 T4 lesions are further subdivided into T4a and T4b. Invasion past the
inner cortex of the thyroid cartilage or invasion of extra-laryngeal structures
deliniate a T4a lesion. 1 Extra-laryngeal structures include the trachea,
esophagus, thyroid tissue, or soft tissues of the neck such as the strap muscles
or deep muscles of the tongue. A T4b lesion invades deeply to the prevertebral
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space, the mediastium, or encases the carotid artery. 4 The utility of T staging for
therapeutic planning and prognosis will be discussed in a different section.

N STAGE:

All laryngeal tumors bear the same N classification system. Presence, size, and
laterality of nodal involvement generate the N stage. The designation Nx is used
when nodal involvement has yet to be or cannot be investigated. An N0 tumor
does not involve any lymph nodes. It is relatively common for a cN0 lesion to be
upstaged after neck dissection once histopathology has revealed occult nodal
involvement. Nodal involvement of 3 cm or less in a single node ipsilateral to the
tumor is classified as N1. 4 The N2 categorization includes nodes less than 6cm
in greatest dimension and is broken down into N2a, N2b, and N2c. Nodes must
remain ipsilateral to the tumor. A single node greater than 3 cm but less than
6cm is designated N2a. 4 Multiple ipsilateral nodes less than 6 cm classifies as
N2b. 4 Bilateral or contralateral nodal involvement less than 6 cm is categorized
as N2c. 4 Once a node is greater than 6 cm in greatest dimension, it is classified
as an N3 node. 4
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M STAGE:

Of all the classifications in the TNM staging system, M stage is most binary.
Patients without metastatic workup at said to have stage Mx disease. The
absence of distant metastasis classifies as M0. The presence of any distant
metastasis is termed M1. 4 The M1 status of a patient is the most foreboding
classification system as it represents a tumor that has evolved to be able to
invade the vascular system and invade at a distant site. Numerous oncogenic
and mutagenic derangements must have occurred to allow this. 1

ADDITIONAL PROGNOSTIC MARKERS

In addition to AJCC staging criteria and other clinical factors that are used to risk
stratify patients and guide treatment, prognostic biologic factors, such as
individual protein expression, mRNA expression patterns, and a few epigenetic
biomarkers have been reported which can independently correlate with outcomes
in laryngeal cancer. The mutational landscape of head and neck squamous cell
cancers was recently reported following whole exome sequencing. Although
novel mutations were identified, no correlation of mutational patterns with
prognosis was performed. In addition, it appears that different subsites of head
and neck cancers may have different mutational trends. 7 Identifying mutational
patterns that carry independent prognostic significance within a subsite would
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help guide future assessment of treatment outcomes and hopefully enable more
individualized treatment approaches. For this reason, a major goal in head and
neck cancer continues to be to identify biologic markers that help to
prognosticate outcomes and can guide treatment. 8

After a review of the literature, the following genes were determined to be
important and interesting targets for investigation: p53, Bcl-2, Ki67, p16ink4,
BNIP3, TGM2, CD24, and Notch 1. These candidate genes are involved in
multiple pathways implicated in carcinogenesis or are shown to be associated
with poorer prognosis in laryngeal squamous cell carcinoma. As an apoptotic
protein, p53 is a commonly mutated gene in solid tumors and is overexpressed in
the majority of head and neck cancer. However, results are inconsistent on p53’s
prognostic relevance. 9 Bcl-2 is a key regulator of cell death and survival that is
commonly expressed in laryngeal cancer with inconsistent prognostic correlation.
9

Ki67 is a protein involved in cell proliferation and is used to estimate the

proliferative rate of tumors. Again, there is disagreement on the utility of Ki67 as
a prognosticator – some previous studies have shown expression to predict
poorer prognosis while others have not shown any correlation. 9 As a cell cycle
regulator, p16ink4 has been implicated in poorer prognosis in patients with cancer
of the larynx. Its expression has also been shown to be anatomical location
specific with predominance in the supraglottic and tonsillar regions. 9

Page 12

The remaining candidate genes represent emerging players in head and neck
cancer. BNIP3 and TGM2 are target genes associated with action of the
transcription factor hypoxia-inducible factor-1 (HIF-1a). 10 BNIP3 is normally
upregulated by hypoxia and, as a member of the BCL-2 family, induces
apoptosis. BNIP3 has been shown to be silenced in tumor cells causing a failure
of apoptosis and association with poorer survival and chemoresistance. TGM2
has been shown to enhance survival in hypoxic cells. Increased expression of
TGM2 has been associated with drug resistance in cancer and worse survival.
CD24 has been studied in a variety of cancers but has recently been described in
laryngeal cancer. 11 Down-regulation inhibits proliferation and induces apoptosis
while increased expression increased tumor growth and propensity for
metastasis. In a recent study, CD24 expression was shown to be associated
with tumor invasiveness and metastasis with high levels of expression associated
with tumor progression. 12 Notch1 is a transmembrane signaling protein whose
function in contextually related to the cells that it is found in. In a recent study
using exome sequencing, Notch1 was shown to acts as a tumor suppressor in
head and neck SCC. 13

SUPRAGLOTTIC CANCER:

While it is convenient to discuss HNSCC as a single entity, it is becoming
increasingly clear that each anatomical site is distinct with regards to diagnosis,
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natural history, and clinical response to treatment. Furthermore, even subsites
(Image 1) appear to represent clinically discrete diseases. Supraglottic tumors
have different behavior and prognosis than glottic and transglottic cancers. 14
Additionally, treatment options for supraglottic squamous cell carcinoma have
been evolving for the last two decades with an emphasis on functional organ
preservation. 8 Supraglottic SCC should be considered a distinct clinical entity.
For this reason, the remainder of the discussion will focus on the supraglottis.

Supraglottic squamous cell carcinoma comprises 30-40% of larynx cancers and
has unique risk for and patterns of regional metastatic spread and local extension
compared to other larynx sub-sites. 1 Patterns of metastatic spread and
extension are primarily due to embryologic characteristics previously discussed
including superficially penetrating lymph vessels, bilateral drainage pattern, and
proximity to the preepiglottic and paraglottic spaces. These factors increased the
likelihood that tumors had nodal involvement at the time of diagnosis. 15
Furthermore, bilateral nodal involvement, more common to supraglottic tumors,
involves a more advanced T stage and overall AJCC stage at time of diagnosis in
many cases.
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MODALITIES OF TREATMENT

There has been considerable advancement in the available treatment options for
supraglottic SCCA over the past decades. Historically, a total laryngectomy
dominated treatment of supraglottic tumors. 16 Over the last three decades,
treatment options have been evolving and have increasingly consisted of organ
preserving strategies. 8 Definitive radiotherapy and chemoradiotherapy treatment
protocols as well as an emphasis on surgical techniques allowing partial
laryngectomy have decreased the use of total laryngectomy (TL) in early stage
tumors and raised questions about it s employment even in more advanced
stages. The idea of non-operative treatment versus operative management of
supraglottic lesions has given way to utilization of a multimodal approach.

TOTAL LARYNGECTOMY

In 1873, Billroth of Vienna performed the first total laryngectomy for laryngeal
cancer. 1 This patient was deceased within 7 months. A patient of Bottini of
Turin who received a total laryngectomy in 1875 lived for 10 years. 1 With much
advancement in anesthesiology, antibiotics, and surgical skill, the total
laryngectomy became, and still is considered the gold standard treatment for
supraglottic lesions.
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The operative basics involve tracheostomy and a large apron incision allowing
access to the midline neck structures. The operation includes disruption of the
hyoid bone and resection inferiorly to include from the epiglottis to below the
cricoid. Ultimately, a stoma is created and bilateral neck dissection in performed
either concurrently or in a staged fashion. 1

Indications of total laryngectomy include cartilaginous invasion of the tumor and
extra-laryngeal spread. 4 Further evidence of advanced disease including
subglottic extension, bilateral arytenoid joint involvement, and hypopharyngeal
involvement typically indicates need for total laryngectomy. 4 In particular
patients, were the risk of aspiration is high or will be detrimental due to underlying
pulmonary disease may also lead to consideration of total laryngectomy. In
addition, salvage total laryngectomy may be necessary after failure of
chemotherapeutic or radiation therapy. Local recurrence and need for
completion laryngectomy after partial laryngectomy can also occur. 1

Complete evaluation of the fitness of the patient prior to the decision to proceed
with any treatment, especially total laryngectomy, is essential. Smee et al.
investigated the importance of fitness for surgery in prognostic evaluation of a
patient with supraglottic carcinoma. 17 He recapitulated what Piccirillo et al,
Sjogren et al, and Paleri et al had demonstrated previously; that comorbidities
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significantly affect survival. 17-20 Smee et al. went on to describe this in general
as ‘fitness for surgery’. 17

With the current range of organ preservation paradigms, it is particularly
important however difficult to decide when total laryngectomy is appropriate.
Principles of individualized and personalized therapy which involve the patient
and their family intimately in the decision-making process will lead to better
patient satisfaction. To achieve this, discourse on the complete range of
treatments available and appropriate for each patient’s lesion and comorbidities
must be started early and ensure patient understanding. The other options for
treatment of supraglottic disease will be discussed below.

OPEN SUPRAGLOTTIC LARYNGECTOMY

Total laryngectomy, although gold standard treatment for supraglottic
malignancies, involves considerable changes in quality of life. In particular, the
loss of voice and difficulty with swallowing can be exceedingly challenging for
patients. Techniques of organ preservation have been evolving in an attempt to
mitigate the disruptive end-results of total laryngectomy. Billroth first performed a
hemilaryngectomy for malignancy in 1874 and techniques for partial laryngeal
surgery have evolved significantly. 1 Open supraglottic laryngectomy,
popularized first by Bocca in Europe and then Som, Ogura, and Kirchner in the

Page 17

United States, is still used at some centers. 21 Benefits of the open supraglottic
laryngectomy include preservation of vocal cord function and lower rates of
tracheotomy dependence. However, the laryngeal framework and supporting
musculature is violated as part of the approach creating swallowing difficulties.
Open partial laryngectomy operations have decreased with an increase in transoral laser microsurgical techniques. 22 Merits of an endoscopic approach will be
discussed in the next section.

ENDOSCOPIC LASER SUPRAGLOTTIC LARYNGECTOMY

Endoscopic use of the CO2 laser by Strong and Jako in 1972 lead to the
establishment of transoral laser microsurgery (TLM) techniques for supraglottic
laryngectomy. 23 A transoral approach eliminates the disruption of musculature
involved in swallowing and maintains the laryngeal cartilagenous suprastructure.
The transoral approach has gained popularity due to advancements in
technology that have improved exposure and visualization. The advent of laser
dissection to remove tumors in a tailor made fashion while avoiding disruption of
the laryngeal framework has helped to reinforce this surgical technique.
Additionally, instant coagulation of tissue surfaces with the laser allows for
piecemeal dissection of a tumor as opposed to the standard oncologic en-bloc
resection. 24 Piecemeal dissection helps to tailor-make resection and increases
the likelihood of a clean margin result.
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The unique feature of true supraglottic lesions in that they do not involved the
cricoarytenoid structures. These structures are the basic functional units of the
larynx and allow for vibration of the vocal cords. Supraglottic laryngectomy,
whether open or endoscopic, attempts to preserve the functional unit of the
cricoarytenoids. Criticism of transoral laser microsurgery tends to surround the
issue of recurrence. Numerous institutional outcomes studies have shown that
recurrence lead to worse outcomes. 25 Radiation and chemotherapy regimens
are used as primary treatment as well as in a multimodal fashion to treat the
disease and decrease the chance of locoregional recurrence. 26 A discussion of
primary radiation and chemotherapy and its utility in a multimodal approach to
supraglottic carcinoma will follow.

IMPLICATIONS OF OPERATIVE MANAGEMENT

As with any significant operation, complications exist and can be considerable.
Early complications include those common to all surgical intervention including
risks of anesthesia, intraoperative bleeding, inability for complete resection,
postoperative infection, and wound dehiscence. 27 Hematoma formation can be
of particular issue due to potential for airway compression and compromise.
Additionally, space-occupying hematoma can stress suture lines and
compromise pharyngeal repairs. Pharyngocutaneous fistula formation can occur
and is especially a risk in patients with poor nutritional status.
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Total laryngectomy leads to an impressive change in how an individual lives their
life. A laryngectomized patient will never again breath from their nose or mouth.
As such, olfaction will no longer occur leading to profound changes in taste.
Furthermore, they will have to undergo extensive therapy to learn to safely
swallow in order to prevent aspiration. Phonation will require either an
electrolarynx, specialized speaking valve, or tracheoesophageal puncture. With
speech therapy, they will be able to develop esophageal speech that, in some
cases, is intelligible. In many cases, nutritional support with a percutaneous
esophagogastrectomy tube will be required and, at times, lifelong.

Organ preserving operative techniques are designed to mitigate the detrimental
effects of a total laryngectomy. Similar complications do arise even with the best
organ preserving operation. Temporary tracheostomy creation may be required
during the operation and in cases of tracheal stenosis unrelieved by dilation in
the postoperative setting. Swallow function is affected, albeit to a lesser extent
than in total laryngectomy, and can require nutritional support with a surgical
feeding tube. 28

Patients must be counseled on the risks, benefits, and changes that will affect
their quality of life prior to undergoing any operation to treat their supraglottic
lesion. Laccourreye (2012) described that some patients desire cure, no matter

Page 20

the means to achieve it. 29 Others may emphasize quality of life after diagnosis
and treatment of their disease. Treatment options must be tailor-made to the
individual patient’s goals and objectives of life after diagnosis with a supraglottic
malignancy. 29

CHEMORADIOTHERAPY

The emphasis of organ preservation in supraglottic carcinoma led to the
investigation of non-operative radiation and chemotherapy-based regimens.
When first employed as definitive treatment strategies for supraglottic carcinoma,
radiation and chemotherapy based protocols touted similar oncologic and
survival outcomes with vastly improved organ preservation. 30 Enhanced organ
preservation, thus, implied better voice quality, swallowing function, and lower
tracheostomy rates. 31 Additionally, another major advantage of
chemoradiotherapy is preservation of surgery as an option for salvage in the
setting of recurrent disease. The use of chemoradiotherapy as part of the
treatment for supraglottic neoplasms has evolved greatly over the last twenty to
thirty years. The current understanding of its utility will be evaluated while
discussing multimodal therapy.

Supraglottic lesions follow the same treatment principles of glottic neoplasms
with the exception that the neck is always treated with radiation due to the higher
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risk of occult nodal disease. Radiation is delivered in multi-dose fractionations up
to 70 Gy to the laryngeal site. 1 The neck is treated bilaterally in supraglottic
disease. A neck dissection may also be considered in definitive chemoradiation
for supraglottic carcinoma. The dosing schedule is rigorous and missed fractions
have been shown to lead to worse outcomes. 32 Therefore, a patient’s ability to
comply must be evaluated before radiation therapy is instituted.

Chemotherapeutic approaches continue to progress as the biology and genetics
of supraglottic squamous cell carcinogenesis is understood. As a part of the
armamentarium, chemotherapy acts to improve the tissue’s sensitivity to
radiation. Although never used in isolation for supraglottic malignancies,
chemotherapy

particularly cisplatin-based therapy, is used either concomitantly

with radiation therapy or as induction for definitive radiation-based treatment. 1 In
addition to its use as part of primarily nonoperative treatment, induction
chemotherapy can be used in a neoadjuvant approach to operative management
of supraglottic lesions. Finally, chemotherapy or chemoradiotherapy is often
employed in the adjuvant setting to operative management. 33

Chemoradiotherapy requires assessment of the entire clinical picture of a patient
as systemic treatment can exacerbate other pathologies. It must also be
recognized that all treatments carry to possibility of significant mobility and
mortality. While surgical management is often criticized as disfiguring and can
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profoundly alter a patient’s quality of life, radiation and chemotherapeutic
treatment strategies have major impacts on an individual’s wellbeing.

Side effects of radiotherapy depend on the size of the field requiring treatment.
Early-stage, small lesions confer minimal complications from radiotherapy. As
the field of treatment grows, complications and side effects become more
considerable. Skin erythema, hoarseness, and dysphagia predominate the selflimiting adverse radiation effects. 1 Hypothyroidism may occur due to the
proximity of thyroid tissue to laryngeal structures. Mucositis and xerositis are
particularly irritating complications for patients and can last indefinitely.
Radioprotecting medications such as amifostine help to prevent and limit these
adverse effects. 1 Arytenoid edema and even necrosis are rarer but more
serious complications. Laryngeal edema and mucositis can increase risks of
aspiration and ultimate respiratory compromise. Odynophagia and dysphagia
can lead to swallowing difficulty and, in some cases, necessitate the use of
percutaneous esophagogastrectomy (PEG) tube placement for nutritional
support. Radiation also leads to significant neck fibrosis that can be
uncomfortable to the patient and complicate operative management in the case
of salvage surgery. 1

Numerous investigations into biologic agents targeting supraglottic squamous cell
carcinomas have introduced the possibility of increased refinement and
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individualization of treatment based on a tumor’s genetic milieu. It is beyond the
scope of this thesis to discuss these agents. However, an individualized
approach to oncologic treatment of supraglottic lesions is a major goal and will
considerably change the treatment of many head and neck neoplasms.

MULTIMODAL THERAPY

Currently, the major focus of treatment is to optimize the chance of cure while
maximizing postoperative laryngeal function and minimizing complications.
Multimodality therapy has become well established in effective treatment of the
disease. While total laryngectomy remains the gold standard oncologic option,
respect for quality-of-life issues surrounding treatment of supraglottic carcinoma
has pushed the field to think differently about approaching a patient with the
disease. Functional larynx preservation can be achieved surgically or nonsurgically. 31 Non-surgical modalities include primary radiation with or without
concurrent chemotherapy. Surgical options include using open or endoscopic
techniques often followed by adjuvant radiation or chemoradiation. Less
aggressive surgery has been combined with adjuvant radiation or chemoradiation
in a multi-modality approach to optimize survival in the face of improved posttreatment laryngeal function. 34 The role of organ-preserving transoral surgery is
not well defined in the overall multimodal treatment of supraglottic SCCA.
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The advent of chemoradiation therapy as well as the amplification of operative
techniques at organ preservation has increased the multidisciplinary approach to
supraglottic cancer. A patient’s healthcare team should include a medical
oncologist, radiation oncologist, head and neck surgeon, oromaxillofacial
surgeon, radiologist, as well as speech and swallow therapist and nutritional
specialist. The multidisciplinary approach has lead to improvements in patient
satisfaction, outcomes, and research collaboration.

THE CHALLENGE OF INSTITUTIONAL STUDIES

As has been described, many therapeutic approaches exist for the treatment of
supraglottic carcinoma. Organ-preserving therapy, in the form of chemoradiation,
has become popular in the United States. Organ-preserving surgical techniques
are available for treatment of early supraglottic carcinoma and appropriately
selected advanced stages. NCCN guidelines do not specify what is the preferred
method of treatment except for specific advanced cases. 4 Anecdotally,
preferences of practice vary with region within the United States. Furthermore,
international practice patterns are even more dramatically different judging by
that the majority of literature on endoscopic and robotic resection emerges from
Europe. Groome et al (2003) compared management of supraglottic neoplasms
in Ontario, Canada with a comparable cohort from the SEER Database. 35 They
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identified profound differences in management practices, however, there were
limited differences in outcomes. Shah et al (1997) accrued data on over 16,000
patients with squamous cell laryngeal cancer and observed diversity in the
management of the disease across the US. 11 Differences in management
existed even between site and stage.

The differences in management strategy are demonstrated by the innumerable
single institutional reviews emerging into the literature. These reports attempt to
describe what they believe to be the choice management strategy for supraglottic
lesions. Implicit in reports on a single management strategy is an inherent
selection-bias of patients appropriate to receive the treatment of interest.
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STATEMENT OF PURPOSE AND HYPOTHESIS

RETROSPECTIVE REVIEW:

Outcomes when transoral laser microsurgery (TLM) is part of a multimodality
approach are not well defined. Current guidelines for early and late stage
disease include the use of TLM, open partial laryngectomy, radiation,
chemotherapy, and total laryngectomy. 4 Current NCCN Head and Neck Cancer
Guidelines for early stage supraglottic carcinoma (T1-2, N0; selected T3) is
endoscopic resection +/- neck dissection, open partial supraglottic laryngectomy
+/- neck dissection, or definitive radiation. 4 Advanced stage disease requires an
increasingly multimodal approach with the possibility of total laryngectomy. 4
What stands out in the guidelines is the absence of consensus on the optimal
treatment option. Therapeutic choice, therefore, becomes a factor of institutional
trends and physician training. An individualized approach to treatment of
supraglottic carcinoma is essential but challenging due to the numerous different
therapeutic modalities available. Currently, attempts in the literature to evaluate
larynx-preserving surgical approaches to supraglottic carcinoma tend to compare
a highly selected patient group receiving the treatment of interest to previously
published data. Furthermore, conclusions of many studies commonly use the
phrase “in a select group of cases” when weighing in on the utility of newer
techniques. This terminology leaves much open to interpretation. What is
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absent from published data, to our knowledge, is a comparison of a
comprehensive cohort of patients receiving all modern treatments for supraglottic
cancer. Overall, the guidelines reflect a lack of consensus regarding optimal
treatment and there is considerable treatment variation between centers.
Although several series in the literature report functional and oncologic outcomes
for selected patients with supraglottic squamous cell carcinoma treated with TLM
there are no complete patient cohorts reporting outcomes with TLM as part of a
multidisciplinary approach including the use of TLM, radiation, chemotherapy,
and total laryngectomy.

The purpose of this observational study is to report on the oncologic and
functional outcomes in a complete cohort of patients without selection based on
stage or treatment type. The goal is to demonstrate how treatment of the
disease, as a whole, has been approached at this institution.

SEER VS. INSTITUTIONAL REVIEW:

Innumerable institutional studies have investigated oncologic outcomes of the
various treatment options for supraglottic neoplasms. Many of these studies
involve a specific treatment and, thus, patient population properly selected for
that treatment. This introduces a selection bias implicit in the institutional studies.
Abstracting all institutional studies in the United States with a comparable SEER
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cohort will allow direct visual comparison of the national trends in the disease
with reports emanating from single institutions. The purpose is to illuminate the
difference between specific study outcomes and national trends in oncologic
outcomes.

HYPOTHESES:

1. Oncologic outcomes will vary based on treatment with transoral laser
microsurgery, total laryngectomy, or definitive radiation based therapy.

2. Functional outcomes after transoral laser microsurgery is superior to both
total laryngectomy and definitive chemoradiotherapy.

3. Multimodality therapy in the form of adjuvant chemoradiation therapy is
associated with improved survival.

4. Survival reported in institutional studies will vary significantly from population
based outcomes.
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MATERIALS AND METHODS

All portions of the retrospective review, systematic review of the literature, and
SEER database analysis including, but not limited to: record review, database
generation, and statistical analysis were conducted by the researcher responsible
for this dissertation.

RETROSPECTIVE REVIEW:

Study Subjects
The Yale University Institutional Review Board approved this study prior to data
compilation and analysis. Patients evaluated with supraglottic SCCA at Yale
New Haven Hospital over a 5 year period between January 1, 2003 and
December 31, 2007 were retrospectively identified. Patients records were
queried using ICD-9 codes for glottis (161.0), supraglottis (161.1), subglottis
(161.2), laryngeal cartilage (161.3), and aryepiglottic fold (148.2). Codes for all
larynx subsites were reviewed to ensure inclusion of patients that may have been
miscoded. CPT codes for open supraglottic laryngectomy (31367, 31368),
horizontal/laterovertical/anterovertical/antero-latero-vertical hemilaryngectomy
(31370, 31375, 31380, 31382), epiglottidectomy (31420), unlisted procedure of
the larynx (31599), and total laryngectomy (31365, 31360) were also searched.
Patients with pathologically confirmed supraglottic squamous cell carcinoma
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were included. The Yale Cancer Center Tumor Registry, a comprehensive
registry of all cancer patients diagnosed, treated, or seen at Yale New Haven
Hospital, was used as an additional check that all patients treated for supraglottic
squamous cell caricinoma had been captured. Patients with distant metastasis
present at the time of diagnosis were excluded from analysis.

A total of 60 patients were identified. One patient did not have complete staging
information and was excluded. Three patients treated with open supraglottic
laryngectomy were excluded from survival and function analysis due to the small
sample size in this treatment group. The remaining 56 patients were included for
analysis. Patients were evaluated in a multidisciplinary fashion in the setting of a
tumor board.

Study Variables
Clinical, pathological, functional, and survival data was collected from the medical
records and entered into an Excel spreadsheet. Demographic data included:
gender, age at diagnosis, smoking/alcohol use, and race. Pathologic and clinical
data included tumor histology, location, TNM stage, AJCC stage, and margin
status. Treatment data collected included total laryngectomy (TL), transoral laser
microsurgery (TLM), and radiation therapy including radiation with or without
chemotherapy either in the definitive or adjuvant setting. Post-treatment
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functional outcome collected included incidence of PEG during treatment, PEG
requirement after treatment, tracheostomy, and complications during treatment.

Statistical Analysis
Differences between treatment modalities and functional outcomes were
measured with Chi-squared analysis. Kaplan-Meier analysis was performed to
establish overall survival outcomes. Further assessment of survival differences
between groups was done with Logrank and Cox regression analysis. Diseasespecific survival could not be acceptably analyzed given the available data.
Statistics were performed using SPSS, Kaplan-Meier curves were generated
using R.
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SEER VS. INSTITUTIONAL REVIEW:

A systematic review on supraglottic squamous cell carcinoma survival outcomes
was performed. The databases queried included: Medline, Embase, Scopus,
and Web of Science. After a preliminary search of the literature, a MeSH
analysis was generated to further refine search terms to enhance capture within
the topic. A total of 687 articles were discovered. Only United States
publications were of interest to increase the comparability between the reports
and SEER outcomes. 385 international papers were excluded. A total of 43
publications included reports supraglottic squamous cell carcinoma. The many
excluded publications reported on glottic cancer, biomarker analysis, or were
review articles without reported institutional outcomes. Of the remaining 43
publications, 18 articles reported data on survival statistics based on treatment
modality for T1-T4 disease (Table 1). From the data reported in these
publications, survival statistics were back-calculated to produce descriptive
survival statistics for each treatment modality investigated and for each stage
represented. No one single publication reported confidence intervals. Therefore,
confidence intervals were calculated using the formula 1.96 x SQRT ( proportion
x ( 1 - proportion / n ) ) where proportion equals the reported or back-calculated
survival. The Survival Epidemiology and End Results (SEER) database for the
National Cancer Institute was query for all patients with supraglottic squamous
cell carcinoma between 1988-2004 was obtained. The proprietary SEER
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database manipulator was used to generate 2- and 5-year overall survival (OS)
and disease specific survival (DSS). Graphic representations of SEER derived
survival statistics compared to institutionally reported survival were created using
Graphpad Prism 6 and Apple Numbers.
15,22,26,30,34,36-49

Table 1: Selected Institutional Reports
Articles selected from a systematic review of the literature that included survival statistics for
each stage of disease. References in order of appearance:
39,34,22,47,36,40,45,44,42,49,43,41,37,38,26,15,46,30,48
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RESULTS

RETROSPECTIVE REVIEW:

Of the 56 patients eligible for analysis 22 (39%) were treated with TLM , 23 (41%)
with XRT/CRT, and 11 (20%) with TL. Neck dissection was performed in 17/22
(77%) of patients treated with TLM and 10/11 (91%) of patients treated with TL.
Adjuvant XRT or CRT was used in 82% of patients treated with TLM and in 82%
of those treated with TL. All patients treated with XRT/CRT received standard
fractionation and dosage. Average follow-up for all patients was 45 months.
There was no significant difference in follow-up between treatment groups.

Patient age, gender, race, T stage and AJCC stage were not associated with 5
year overall survival (OS) (table 2). Among tumor and patient characteristics only
treatment modality was statistically associated with OS (p = 0.009), confirming
our first hypothesis. Smoking status approached significance (p = 0.087). There
was not a significant difference in the distribution of stage between treatment
groups (p = 0.454). Five patients with pathologically T3 disease were treated
with TL; 3 had large transglottic tumors or post-cricoid involvement, 1 was
downstaged to T3 after being clinically staged T4, and 1 patient was unable to
complete treatment with CRT due to renal failure and was subsequently
treatment was converted to TL (table 3).
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Local recurrence for TLM, TL, and XRT/CRT was 1/20 (5%), 0/11 (0%), and 1/11
(9%) (Table 4). Chronic gastrostomy tube use for TLM, TL, and XRT/CRT was
3/20 (15%), 4/11 (36%) and 5/10 (50%). Chronic tracheostomy for TLM, TL, and
XRT/CRT was 0/21 (0%), 11/11 (100%), and 7/20 (35%) (Table 5). Two year
overall survival for TLM, TL, and XRT/CRT was 86% (18/21), 80% (8/10) and
52% (12/23). Kaplan-Meier survival curves by treatment modality are shown in
Figure 1. There was a significant difference in overall survival between treatment
groups based on Log Rank analysis (p = 0.009), supporting hypotheris 1. No
significant difference was found between AJCC stages (p = 0.471).
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In unadjusted cox regression analysis (table 6), survival was significantly different
between treatment groups (p = .015), indicating a survival risk to receiving XRTbased therapy. Receiving adjuvant radiation therapy following surgery conferred
a significant survival benefit (HR = 3.475, p = 0.001). This confirms our third
hypothesis. Age less than fifty was significantly associated with improved
survival compared to age greater than seventy (HR = 11.363, p = 0.021).
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In multivariate analysis (Table 7) , the significance of treatment remained when
adjusting for AJCC stage. This significance was lost, however, when adjusting
for adjuvant therapy and incidence of recurrence. When adjusting for stage of
disease and patient age, XRT-based therapy carried a significant survival risk
over receiving a TL (HR = 0.245, p = 0.028). Furthermore, patient age remained
significant with a survival benefit in patients less than 50 years old (HR = 10.816,
p = 0.032).
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Hazard Ratio
Treatment Modality
TLM (v. XRT-based)
TL (v. XRT-based)

0.721
0.245

95% CI

P-value

0.343 - 1.515
0.070 - .857

0.084
0.388
0.028

Adjusted for:
AJCC Stage
Tx, Stage, and Age
Age
50-70yo (v. <50yo)
>70yo (v. <50yo)

Adjusted for:
Tx and Age

0.861 - 52.211
1.229 - 95.163

0.089
0.069
0.032

0.329 - 1.409
0.073 - 0.861

0.078
0.301
0.028

6.041
9.003

0.780 - 46.806
1.085 - 74.701

0.110
0.085
0.042

Treatment Modality
TLM (v. XRT-based)
TL (v. XRT-based)

1.174
0.670

0.435 - 3.173
0.135 - 3.339

0.675
0.751
0.626

Adjuvant Therapy
XRT
CT/XRT

3.333
2.722
4.293

1.099 - 10.106
0.812 - 9.124
1.122 - 16.434

0.033
0.105
0.033

Treatment Modality
TLM (v. XRTbased)
TL (v. XRT-based)
Age
50-70yo (v. <50yo)
>70yo (v. <50yo)

Adjusted for:
Tx and Adjuvant
therapy

0.565
6.704
10.816

0.681
0.252

Table 7. Multivariate Cox Regression Analysis.
In an multivariate regression model, XRT-based therapy conferred a significant risk to
survival only compared to TL when controlling for stage and age. Receiving adjuvant
therapy provided a significant survival benefit. Reference variables: XRT-based, Stage I,
Age <50yo, adjuvant Tx, no locoregional recurrence
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TL

TLM

XRT-based

Figure 1: Kaplan-Meier Survival Curve based on Therapeutic Modality
Survival curves for each therapeutic modality are shown. A log rank analysis demonstrated
significance in survival (p = 0.009)

Figur
e 2.

IV
III
I
II

Figure 2: Kaplan-Meier Survival Curve based on AJCC Stage
Survival curves for each therapeutic modality are shown. A log rank analysis demonstrated
lack of statistically significant difference in survival (p = 0.471).
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SEER VS. INSTITUTIONAL REVIEW
A visual representation of institutionally reported survival statistics compared to
SEER database generated survival statistics are shown in Figures 3-5. The 2and 5-year overall survival and disease specific survival generated from the
query of the SEER Database were used as zero lines on the graphic
representations. The number of institutional reports included on the graphics
were dependent on what statistical outcomes each publication presented.
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Figure 3: 5-year Overall Survival
SEER-derived 5yr OS for supraglottic cancer is 42%. Individual institutional reported 5yr OS are demonstrated with
hazard ratios. Bracketed numbers reference articles shown in Table 1.
SSL = subtotal supraglottic laryngectomy, ND = neck dissection, RT = Radiation, TL = total laryngectomy
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Figure 4: 5-year Disease Specific Survival
SEER-derived 5yr DSS for supraglottic cancer is 67%. Individual institutional reported 5yr DS are demonstrated with
hazard ratios. Bracketed numbers reference articles shown in Table 1.
SSL = subtotal supraglottic laryngectomy, ND = neck dissection, RT = Radiation, TL = total laryngectomy
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These findings support our fourth hypothesis.
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Figure 5: Survival statistics for each stage of disease
SEER-derived survival statistics for supraglottic cancer is presented along side individual
institutional reported survival statistics demonstrated with hazard ratios. Bracketed numbers
reference articles shown in Table 1.
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DISCUSSION

Since Billroth first performed a hemilaryngectomy for malignancy in 1874,
techniques for partial laryngeal surgery for SSCC have evolved significantly. 50
Open supraglottic laryngectomy, popularized first by Bocca in Europe and then
Som, Ogura, and Kirchner in the United States, is still used at some centers. 21
Endoscopic use of the CO2 laser by Strong and Jako in 1972 lead to the
establishment of TLM techniques for supraglottic laryngectomy. 23

There remains controversy in the management strategy for supraglottic SCCA.
The historical use of total laryngectomy as the gold standard treatment modality
gave way in to primary treatment with chemoradiation to maximize laryngeal
preservation, saving surgery for salvage. The initial role of chemoradiationbased therapy has been supported by landmark studies, most notably the
Veteran Affairs Larynx Cancer Study4 and the RTOG 91-11study. 51 These trials
have been essential to improving larynx preservation. Overall, the application of
radiation and chemotherapy at the population level for organ preservation
remains associated with some controversy. 52 These and other commentaries
challenge the application of the landmark VA and RTOG studies to a broadbased population. 8 The generalizability of these findings are controversial
especially after a report by Hoffman, et al. observed that laryngeal cancer is the
only anatomical site that has seen decreased survival in the US over the last two
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decades. 8 The supraglottic subsite appears to play an important role in the
observed diminished survival. Hoffman, et al. went on to show that this decrease
in survival coincides with the change in treatment priorities to less aggressive
primary treatment with chemoradiation rather than surgery. 8 This observation
was confirmed by Zhang et al. however, this group did not find a decreased
survival in patients receiving RT since 1994. 53 In a population based study,
Chen & Halpern concluded that TL provides best chance of survival in patients
with advanced disease. 32 Developments in surgical technique have been
occurring, resulting in better functional outcomes. Chemoradiation regimens
have been refined as well. However, there is a lack of consensus on what is the
best practice for treating supraglottic lesions.

The treatment options for supraglottic SCCA have evolved over the last two
decades. The goal of oncologic cure and functional laryngeal preservation
influenced the predominant use of non-operative management with radiation and
chemoradiation in the United States. Total laryngectomy and subtotal
supraglottic laryngectomy via an open or endoscopic approach are also options
within the modern armamentarium for supraglottic SCCA. Numerous institutional
studies have been published reporting outcomes for open and transoral
supraglottic laryngectomy and have been paramount is describing the feasibility
and efficacy of each modality. 54 In general, these reports include series of
patients selected based on tumor characteristics including stage as well as
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patient characteristics including fitness for surgery, and do not report patients
treated with alternate modalities. These studies commonly focus on a particular
technique to report on or compare to previously published results. The benefit
has been the introduction and validation of important techniques used to treat
supraglottic cancer. However, many studies involved precise selection criteria
based on tumor characteristics or stage of disease. Inherent to such selection
processes is a level of bias introduced to statistical analysis. Furthermore, in the
clinical setting the decision on what treatment to offer involves countless
individual patient parameters. Study selection criteria augments the reality of
clinical medicine - practicing medicine involves offering treatment options to
patients where as, in the research environment, patients are selected for a
certain treatment. To some degree, because of this, the role of transoral laser
microsurgery in the multidisciplinary care of supraglottic squamous cell cancer
remains ill defined.

The present study took an approach similar to clinical medicine - the only
selection criteria was that a patient had a supraglottic squamous neoplasm. This
study is the first that we are aware of which includes a complete cohort of
patients with supraglottic squamous cancer treated with multiple modalities
including TLM. Multiple treatment modalities were considered before a specific
treatment was recommended for each patient; an intent-to-treat design. Patients
of all stages were included. This study design allowed a side-by-side analysis of
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all treatment types and stages without issues of dropout or crossover. Given the
inclusion of many modern treatment modalities and all stages of disease, the
study represents a less biased comparison in the analysis of functional and
survival outcomes. The result is a reporting of our institutional approached to
supraglottic cancer.

The results of the current study demonstrate a diminished survival in patients
treated with XRT-based therapy when compared to TL and TLM. When
controlling for both stage and age, XRT-based treatment nonetheless carries a
survival risk when compared to TL. This reduced survival in the radiotherapy
group may be secondary to poorer performance status or other confounding
factors not captured in the available data. Poor performance status may have
precluded operative management and, as Smee et al. illustrate, fitness for
surgery significantly affects overall survival. 17

Transoral laser microsurgery was superior to XRT-based treatment in direct
comparison and when controlling for stage of disease. Interestingly, the
significance of the difference was lost when controlling separately for age,
adjuvant treatment, and recurrence. This may represent the difficult nature of
this disease, but may also emphasize important factors to survival such as the
use of adjuvant treatment and the impact of disease recurrence. In addition, a
dramatic decrease in survival at the 5-year point was seen in both TLM and XRT-
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based treatment. Interpretation of this observation becomes difficult as the
sample-size is small.

In this series, the prescription of adjuvant therapy significantly improved survival
when adjusting for treatment. More specifically, chemoradiation-based adjuvant
therapy conferred a survival advantage in this cohort. Interestingly, when
controlling for adjuvant therapy, there were no survival differences seen between
treatment groups. Given the large percentage of patients getting adjuvant
treatment after TL and TLM, these results reinforce the importance of a
multimodal approach to supraglottic SCCA. This finding deserves further
exploration to explain the importance of chemotherapy-based adjuvant treatment
in the setting of surgical management of supraglottic neoplasms.

Several prognostic factors reported in the literature are reevaluated in this cohort.
Age greater than 70 years old emerged as a significant survival risk in our data
analysis. The importance of patient age has been reported in the literature. 47
Disease recurrence is an important prognostic factor implicated in survival
outcomes. 55 Contrary to expectation, recurrence did not have a significant
impact on survival in univariate or multivariate analysis, although there was a
significant difference in the incidence of recurrence between treatment groups in
this study. This is inconsistent with Sessions et al. who associated decreased
survival with recurrence. 47 The differences in this study may be explained by the
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size of this study as well as the inclusion of all treatment groups. For instance,
Sessions et al. did not include patients receiving chemotherapy-based treatment
in the data that lead to their conclusion associating recurrence with decreased
survival. 47 Further investigation should focus on the importance of margin status
and its relation to disease recurrence in the analysis of survival outcomes. Other
clinical prognosticators typically described in the literature include nodal status
and specific site involvement, such as the preepiglottic space and the vallecula.
56

The relatively small size of this study may be responsible for those not

reaching statistical significance in our study.

Patient quality of life measures are important in the treatment of SSCC because
of the significant morbidity in speech and swallow function that can occur as a
result of these tumors and its treatment. Considerations of quality-of-life add to
the complex nature of therapeutic decision-making. As Laccourreye et al. aptly
describe in their recent study, a careful evaluation of the attitudes and opinions a
patient has regarding their own survival or functional impairments is essential. 29
Multiple authors have published on advantages of post-operative function after
TLM including reduced impact on swallowing, decreased length-of-stay, and
shorter PEG tube and tracheostomy duration. 32 In our study, functional
outcomes were comparable across treatment groups except for where
differences were anticipated, such as the TL group. Although not statistically
significant, the data illustrated the performance benefit of TLM compared to all
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other treatments. No patients in the TLM group were chronically tracheotomy
dependent. Percutaneous endoscopic gastrostomy (PEG) tube requirement in
the TLM group was 15%, but lower than in both the TL and XRT groups. This
study demonstrates that XRT-based treatment is not without morbidity and, on
the whole, has a higher incidence of functional impairment when compared to
TLM. The rates of functional outcome measures are high for each treatment
modality compared to other published series, which may be due in part to
comorbidity and pre-treatment health status.

The study is limited by its retrospective nature. Records were incomplete in
some cases, limiting our ability to analyze post-operative function, recurrence,
and cause of death. Moreover, while the size of the entire cohort is within the
upper range of previously published series, subgroup sample sizes are small,
making it difficult to draw conclusions between groups. A larger sample size
would improve multivariate comparisons by increasing the ability to control
survival analysis for multiple factors, simultaneously.

As has been previously discussed, numerous institutions have published
oncologic outcomes for a variety of treatment modalities. These reports, as a
whole, tend to investigate a single modality of therapy. As alluded to, such
reports may introduce a degree of selection bias as patients have already been
selected as appropriate candidates for the treatment of interest. We
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hypothesized that this introduces outcomes that are not entirely representative of
the overall nature of the disease. Figures 3-5 show the reported oncologic
survival compared to national survival statistics generated by the SEER
Database. As hypothesized, institutionally reported survival tends to be superior
to national survival. This trend is especially consistent with reported overall
survival, which is arguably more important to a patient than disease specific
survival. When extrapolated by stage, institutional survival remains elevated
above national statistics primarily for early stage disease. There is increased
variation in survival at more advanced stage disease likely representing the
difficulty treating complex lesions with more aggressively invasive components.

The graphics presented here represent a birds-eye view of survival after treating
supraglottic carcinoma. There is a range of survival reported by single
institutions and they tend to be superior to national survival trends. What this
demonstrates is a need for emphasis on multi-institutional trials or increased
utilization of population-based investigation. Taken in the context of our
retrospective study in which we attempted to report with an intent-to-treat model
looking at oncologic and functional outcomes of patients with supraglottic
neoplasms, efforts should be made to further investigate the successes in
treating the disease in a comprehensive fashion.
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CONCLUSION

Today, the complexity of supraglottic cancer is further complicated by the variety
of treatment options available and their application in a multimodal fashion.
Since this study involved the observations of a comprehensive cohort, these
results are important to the overall treatment of a patient presenting with primary
supraglottic SCCA. Our study reports a comprehensive cohort of patients with
SSCC treated in a multimodality fashion, including the use of TLM. Total
laryngectomy performed the best in terms of survival. Amongst the organ
preserving treatments, XRT-based primary therapy was associated with
decreased survival risk, although selection bias would be expected with poorer
performing patients being treated with XRT. The increasing expertise in
microsurgical and CO2 laser-based resection has improved upon the surgical
options for functional laryngeal preservation. As reinforced by this study,
transoral laser microsurgery, especially when employed in a multimodal
approach including adjuvant chemoradiotherapy, offers acceptable oncologic
results and good functional outcomes.
As a comprehensive approach to studying the treatment of supraglottic
cancer, this study has important relevance. Future investigation into supraglottic
SCCA deserves a well-designed and comprehensive prospective observation
similar to this series. This study and further prospective studies will help to
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improve the understanding of therapeutic decision-making and lead to better
success with treating supraglottic cancer.
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